US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

RZLT

Rezolute (RZLT)

Rezolute Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RZLT

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/05/2024	15:21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RZLT	Rezolute Inc
15/05/2024	15:25	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RZLT	Rezolute Inc
15/05/2024	15:05	GlobeNewswire Inc.	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update	NASDAQ:RZLT	Rezolute Inc
23/04/2024	07:00	GlobeNewswire Inc.	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	NASDAQ:RZLT	Rezolute Inc
11/03/2024	09:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RZLT	Rezolute Inc
06/03/2024	06:30	GlobeNewswire Inc.	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	NASDAQ:RZLT	Rezolute Inc
13/02/2024	16:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:RZLT	Rezolute Inc
13/02/2024	15:05	GlobeNewswire Inc.	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update	NASDAQ:RZLT	Rezolute Inc
24/01/2024	07:00	GlobeNewswire Inc.	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	NASDAQ:RZLT	Rezolute Inc
23/01/2024	07:00	GlobeNewswire Inc.	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	NASDAQ:RZLT	Rezolute Inc
14/12/2023	07:00	GlobeNewswire Inc.	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism	NASDAQ:RZLT	Rezolute Inc
13/12/2023	07:00	GlobeNewswire Inc.	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)	NASDAQ:RZLT	Rezolute Inc
29/11/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:RZLT	Rezolute Inc
22/11/2023	16:16	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:RZLT	Rezolute Inc
17/11/2023	07:00	GlobeNewswire Inc.	Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day	NASDAQ:RZLT	Rezolute Inc
15/11/2023	08:08	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:RZLT	Rezolute Inc
13/11/2023	15:05	GlobeNewswire Inc.	Rezolute Reports First Quarter Fiscal 2024 Results	NASDAQ:RZLT	Rezolute Inc
17/10/2023	07:00	GlobeNewswire Inc.	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism	NASDAQ:RZLT	Rezolute Inc
13/10/2023	15:30	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:RZLT	Rezolute Inc
11/10/2023	07:00	GlobeNewswire Inc.	Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism	NASDAQ:RZLT	Rezolute Inc
14/09/2023	15:22	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:RZLT	Rezolute Inc
14/09/2023	15:05	GlobeNewswire Inc.	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress	NASDAQ:RZLT	Rezolute Inc
06/09/2023	06:00	GlobeNewswire Inc.	Rezolute to Participate in Upcoming Investor Conferences in September	NASDAQ:RZLT	Rezolute Inc
27/06/2023	15:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:RZLT	Rezolute Inc
27/06/2023	15:05	GlobeNewswire Inc.	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism	NASDAQ:RZLT	Rezolute Inc
11/05/2023	15:25	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:RZLT	Rezolute Inc
11/05/2023	15:05	GlobeNewswire Inc.	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress	NASDAQ:RZLT	Rezolute Inc
03/05/2023	07:56	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:RZLT	Rezolute Inc
12/04/2023	15:20	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:RZLT	Rezolute Inc
23/03/2023	15:50	GlobeNewswire Inc.	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema	NASDAQ:RZLT	Rezolute Inc

Showing the most relevant articles for your search:NASDAQ:RZLT

1 2 3 Próxima >

Vontobel Financial Produ...

CAC 40 Cumulat Div

Societe Generale Effekten

Investec Bnk 23

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones